Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients
Therapeutic Advances in Musculoskeletal Disease, Volume 14, Year 2022
Notification
URL copied to clipboard!
Description
Background: Visual involvement is the most feared complication of giant cell arteritis (GCA). Information on the efficacy of tocilizumab (TCZ) for this complication is scarce and controversial. Objective: We assessed a wide series of GCA treated with TCZ, to evaluate its role in the prevention of new visual complications and its efficacy when this manifestation was already present before the initiation of TCZ. Design: This is an observational multicenter study of patients with GCA treated with TCZ. Methods: Patients were divided into two subgroups according to the presence or absence of visual involvement before TCZ onset. Visual manifestations were classified into the following categories: transient visual loss (TVL), permanent visual loss (PVL), diplopia, and blurred vision. Results: Four hundred seventy-one GCA patients (mean age, 74 ± 9 years) were treated with TCZ. Visual manifestations were observed in 122 cases (26%), of which 81 were present at TCZ onset: PVL (n = 60; unilateral/bilateral: 48/12), TVL (n = 17; unilateral/bilateral: 11/6), diplopia (n = 2), and blurred vision (n = 2). None of the patients without previous visual involvement or with TVL had new episodes after initiation of TCZ, while only 11 out of 60 (18%) patients with PVL experienced some improvement. The two patients with diplopia and one of the two patients with blurred vision improved. Conclusion: TCZ may have a protective effect against the development of visual complications or new episodes of TVL in GCA. However, once PVL was established, only a few patients improved. © The Author(s), 2022.
Authors & Co-Authors
Loricera, Javier
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Castañeda, Santos
Spain, Madrid
Universidad Autónoma de Madrid
Moriano, Clara
Spain, Leon
Complejo Asistencial Universitario de León
Narváez, Javier A.
Spain, Barcelona
Hospital Universitari de Bellvitge
Maíz Alonso, Olga
Spain, Donostia-san Sebastian
Osakidetza, Donostia University Hospital
Romero-Yuste, Susana María
Spain, Pontevedra
Complejo Hospitalario Universitario de Pontevedra
Callejas-Rubio, José Luís
Spain, Granada
Hospital Universitario San Cecilio
Galíndez Agirregoikoa, Eva
Spain, Bilbao
Osakidetza, Basurto University Hospital
Sivera, Francisca
Unknown Affiliation
Galisteo, Carlos
Spain, Barcelona
Hospital Parc Taulí
Ferraz-Amaro, Iván
Spain, Santa Cruz de Tenerife
Hospital Universitario de Canarias
Sánchez-Martín, Julio
Spain, Madrid
Hospital Universitario 12 de Octubre
Sánchez-Bilbao, Lara
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Calderon-Goercke, Mónica
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Herńandez, José L.
Spain, Santander
Hospital Universitario Marqués de Valdecilla
González-Gay, Miguel Ángel
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Blanco-Alonso, Ricardo
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Statistics
Citations: 3
Authors: 17
Affiliations: 17
Identifiers
Doi:
10.1177/1759720X221113747
ISSN:
1759720X